# Novel Sjogren's Drug Passes First Phase III Test

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/acr/123854) · 2026-11-12 · Medicine
Page: https://themorning.science/story/novel-sjogren-s-drug-passes-first-phase-iii-test-775be665f38a3a90
Kind: research · Impact: medium

## In brief

- Dazodalibep, an investigational CD40L antagonist, was tested in a 48-week phase III trial for Sjögren's disease.
- Results reported at the ORLANDO meeting suggest the drug is nearing the finish line on the way to approval, according to MedPage Today.

## Why it matters

A positive phase III result is a key step toward a new treatment option for Sjögren's disease, a condition with few approved disease-modifying drugs.

## Timeline

- 2026-11-12: 48-week phase III results for dazodalibep reported at the ORLANDO meeting

## Coverage

- [Novel Sjogren's Drug Passes First Phase III Test](https://www.medpagetoday.com/meetingcoverage/acr/123854) — MedPageToday.com - medical news for physicians, 2026-11-12

Tags: sjogren's, clinical trials, autoimmune disease, drug development, dazodalibep

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science